This article, with insights from Hong Li, Ph.D., Head of Formulation, and Lixia Zhang, Director of Analytical Service, CMC, BioDuro, was originally published in The Pharma Navigator, August 26, 2026. Visit the website: The Pharma Navigator.

Oral peptide therapeutics offer significant potential to combine the benefits of peptide-based medicines with the convenience of oral dosing. However, poor bioavailability, enzymatic degradation, manufacturing sensitivities, and complex analytical requirements continue to present significant development challenges.

In this interview, BioDuro experts Hong Li and Lixia Zhang discuss strategies for overcoming these barriers, from permeation enhancers, enteric coatings, and lipid-based delivery systems to low-stress manufacturing approaches and advanced analytical workflows. They also explore why successful oral peptide development requires balancing bioavailability, patient variability, manufacturability, and clinical performance.

Read the full article to learn more about advancing oral peptide therapeutics from formulation through analytical development.